Bibliography

The following documents were considered in the construction and writing of this site.

1)  American Association of Clinical Endocrinologists Medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients—2002 update Petak S.M., Nankin H.R., Spark R.F., Swerdloff R.S., Rodriguez-Rigau L.J.: AACE Hypogonadism Guidelines, Endocr Pract. 2002;8(No. 6).
2)  Harman SM, Metter EJ, Tobin JD, et al.: Longitudinal effects of ageing on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab (United States), Feb 2001, 86(2) p724-31.
3) Tengstrand B.; Carlstrom K.; Hafstrom.: Bioavailable testosterone in men with rheumatoid arthritis-high frequency of hypogonadism. Rheumatology (Oxford) 2002 Mar;41(3):285-9 (ISSN: 1462-0324).
4) Handout on Health: Rheumatoid ArthritisThe National Institute of Arthritis and Musculoskeletal and Skin Diseases Publication Date: January 1998 Revised November 1999 http://www.niams.nih.gov/hi/topics/arthritis/rahandout.htm
5) Dabbs J.M.: Age and seasonal variation in serum testosterone concentration among men. Chronobiol Int 1990;7(3):245-9(ISSN: 0742-0528).
6) Valcour A. Testosterone Free T or not T Free 1/11/2001 L925-0102-1 6211230601 Laboratory Corporation of America
7) Smith K.W.; Feldman H.A.; McKinlay J.B.: Construction and field validation of a self-administered screener for testosterone deficiency (hypogonadism) in ageing men. Clin Endocrinol (Oxf) 2000 Dec;53(6):703-11 (ISSN: 0300-0664)
8) K. M. Main, I. M. Schmidt, N.E. Skakkebæk.: A Possible Role for Reproductive Hormones in Newborn Boys: Progressive Hypogonadism without the Postnatal Testosterone Peak JCEM, No. 12 4905-4907 2000.
9) Kutlu N; Ekerbicer N; Ari Z; Uyanik BS; Zeren T; Tan U.: Testosterone and nonverbal intelligence in right-handed men with successful and unsuccessful educational levels. Int J Neurosci 2001;111(1-2):1-9 (ISSN: 0020-7454)
10) Dey J, Shepherd M.D.: Evaluation and treatment of erectile dysfunction in men with Diabetes Mellitus. Mayo Clin Proc 2002 Mar;77(3):276-82
11) Leder B.Z.; Le Blanc K.M.; Schoenfeld D.A.; Eastell R.; Finkelstein J.S.: Differential effects of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab 2003 Jan;88(1):204-10 (ISSN: 0021-972X).
12) Herzog A.G.: Altered reproductive endocrine regulation in men with epilepsy implications for reproductive function and seizures. Ann Neurol (United States), May 2002, 51(5) p539-42.
13) Traggiai C.; Stanhope R.: Delayed puberty. Best Pract Res Clin Endocrinol Metab 2002 Mar;16(1):139-51 (ISSN: 1521-690X)
14) Daniell H.W. Narcotic-induced hypogonadism during therapy for heroin addiction. J Addict Dis 2002;21(4):47-53 (ISSN: 1055-0887)
15) Tan R.S.: Andropause: introducing the concept of ‘relative hypogonadism’ in aging males. Int J Impot Res 2002 Aug;14(4):319 (ISSN: 0955-9930).
16) Rapoport D. Whither preventive medicine?: CMAJ 2003 Jan 7;168(1):11; author reply 12 (ISSN: 0820-3946)
17) Woodhouse L.J., Reisz-Porszasz S., Javanbakht M., et al.: Development of Models to Predict Anabolic Response to Testosterone Administration in Healthy Young Men [epub ahead of print] [Record Supplied By Publisher] Am J Physiol Endocrinol Metab , Jan 7 2003.
18) Franklin S.L.; Geffner M.E.: Precocious puberty secondary to topical testosterone exposure. [In Process Citation] J Pediatr Endocrinol Metab 2003 Jan;16(1):107-10
19) Booth A., Johnson D.R., Granger D.A, et al.: Testosterone and child and adolescent adjustment: the moderating role of parent child relationships. [In Process Citation] Dev Psychol (United States), Jan 2003, 39(1) p85-98.
20) Holm M.; Rajpert-De Meyts E.; Andersson A.M.; Skakkebak N.E.: Leydig cell micronodules are a common finding in testicular biopsies from men with impaired spermatogenesis and are associated with decreased testosterone/LH ratio. [Record Supplied By Publisher] J Pathol 2003 Mar;199(3):378-386 (ISSN: 0022-3417).
21) Gupta M.K., Brown D.C., Faiman C., et al.: Effect of low-dose testosterone treatment on androgen regulated proteins prostate specific antigen and sex hormone binding globulin in short pre-pubertal boys: lack of initiation of puberty [In Process Citation]J Pediatr Endocrinol Metab (England), Jan 2003, 16(1) p55-62.
22) Naderi A.R, Safarinejad M.R. Endocrine profiles and semen quality in spinal cord injured men [In Process Citation] Clin Endocrinol (Oxf) (England), Feb 2003, 58(2) p177-84
23) Rolf C, von Eckardstein S, Koken U, et al. Testosterone substitution of hypogonadal men prevents the age dependent increases in body mass index, body fat and leptin seen in healthy ageing men: results of a cross-sectional study.Eur J Endocrinol (England), Apr 2002, 146(4) p505-11.
24) Chatterjee R.; Kottaridis P.D.; McGarrigle H.H.; Linch D.C. Management of erectile dysfunction by combination therapy with testosterone and Sildenafil in recipients of high-dose therapy for haematological malignancies. Bone Marrow Transplant 2002 Apr;29(7):607-10 (ISSN: 0268-3369)
25) Sequera A.M., Fideleff H.L., Boquete H.R., et al. Basal ultrasensitive LH assay a useful tool in the early diagnosis of male pubertal delay?J Pediatr Endocrinol Metab (England), May 2002, 15(5) p589-96.
26) Cicognani A., Alessandroni R., Pasini A., et al. Low birth weight for gestational age and subsequent male gonadal function. J Pediatr (United States), Sep 2002, 141(3) p376-9
27) Ibanez L, Valls C., Cols M., Ferrer A., Marcos M.V., De Zegher F. Hypersecretion of FSH in infant boys and girls born small for gestational age. J Clin Endocrinol Metab. 2002 May;87(5):1986-8.
28) Vaiani E.; Ciocca M.; Cuarterolo M.; Imventarza O.; Rivarola M.A.; Belgorosky A. Hypothalamic-pituitary-testicular function in prepubertal children with chronic liver disease. J Pediatr Endocrinol Metab 2002 Mar;15(3):289-95
29) Main K.M.; Schmidt I.M.; Toppari J.; Skakkebaek N.E. Early postnatal treatment of hypogonadotropic hypogonadism with recombinant human FSH and LH. Eur J Endocrinol 2002 Jan;146(1):75-9 (ISSN: 0804-4643)
30) Smith S.; Wheeler M.J.; Murray R.; O’Keane V. The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. J Clin Psychopharmacol 2002 Apr;22(2):109-14 (ISSN: 0271-0749)
31) Heaton J.P.; Morales A. Endocrine causes of impotence (nondiabetes). Urol Clin North Am 2003 Feb;30(1):73-81 (ISSN: 0094-0143)
32) Zitzmann M; Brune M; Nieschlag E. Vascular reactivity in hypogonadal men is reduced by androgen substitution.J Clin Endocrinol Metab 2002 Nov;87(11):5030-7 (ISSN: 0021-972X)
33) Kilciler G.; Ozata M.; Oktenli C.; Sanisoglu S.Y; Bolu E.; Bingol N.; Kilciler M. Ozdemir I.C.; Kutlu M. Diurnal leptin secretion is intact in male hypogonadotropic hypogonadism and is not influenced by exogenous gonadotropins. J Clin Endocrinol Metab 2002 Nov;87(11):5023-9 (ISSN: 0021-972X)
34) Johansson A., Ahren B., Forsberg H., et al. Testosterone and diurnal rhythmicity of leptin, TNFalpha and TNFII receptor in insulin-resistant myotonic dystrophy patients. Int J Obes Relat Metab Disord (England), Oct 2002, 26(10) p1386-92
35) Cui Y.G., Yang X.F., Song L., et al. Continuous measurement of urine beta-FSH excretion in men with hypogonadism. Zhonghua Nan Ke Xue (China), 2002, 8(3) p194-7
36) Casey R.W. COUNTERPOINT. Urologists should take an active role in the diagnosis and treatment of hypogonadism in the aging male. [In Process Citation] Can J Urol (Canada), Dec 2002, 9(6) p1681-3.
37) Depenbusch M, von Eckardstein S, Simoni M, et al. Maintenance of spermatogenesis in hypogonadotropic hypogonadal men with Human Chorionic Gonadotropin alone. Eur J Endocrinol (England), Nov 2002, 147(5) p617-24
38) Gerstenbluth RE, Maniam PN, Corty EW, et al. Prostate-specific antigen changes in hypogonadal men treated with Testosterone replacement. [In Process Citation] J Androl (United States), Nov-Dec 2002, 23(6) p922-6.
39) Zitzmann M., Brune M., Vieth V, et al. Monitoring bone density in hypogonadal men by quantitative phalangeal ultrasound. Bone (United States), Sep 2002, 31(3) p422-9.
40) Boos C.J., Matfin G.: Klinefelter’s syndrome manifesting as an acute pulmonary embolus in a 52-year-old man. Endocr Pract (United States), Jan-Feb 2002, 8(1) p68-9.
41) Huang J.S., Wilkie S.J., Dolan S., et al. Reduced testosterone levels in human immunodeficiency virus infected women with weight loss and low weight. Clin Infect Dis (United States), Feb 15 2003, 36(4) p499-506
42) Ferrando A.A., Sheffield-Moore M., Paddon-Jones D., et al. Differential anabolic effects of testosterone and amino acid feeding in older men. J Clin Endocrinol Metab (United States), Jan 2003, 88(1) p358-62
43) Cermik D., Selam B., Taylor H.S. Regulation of HOXA-10 expression by testosterone in vitro and in the endometrium of patients with Polycystic Ovary Syndrome. J Clin Endocrinol Metab (United States), Jan 2003, 88(1) p238-43
44) Colao A., Di Somma C., Spiezia S., et al. Effect of growth hormone (GH) and/or testosterone replacement on the prostate in GH deficient adult patients.J Clin Endocrinol Metab (United States), Jan 2003, 88(1) p88-94.
45) Pope H.G., Cohane GH, Kanayama G., et al. Testosterone gel supplementation for men with refractory depression: randomized, placebo-controlled trial. Am J Psychiatry (United States), Jan 2003, 160(1) p105-11
46) Oefelein M.G.. Health related quality of life using serum testosterone as the trigger to dose long acting depot luteinizing hormone-releasing hormone agonists in patients with prostate cancer. J Urol (United States), Jan 2003, 169(1) p251-5
47) Cussons A.J., Bhagat C.I., Fletcher S.J., et al. Brown-Sequard revisited: a lesson from history on the placebo effect of androgen treatment. Med J Aust (Australia), Dec 2-16 2002, 177(11-12) p678-9.
48) Perry P.J., Yates W.R., Williams R.D., et al. Testosterone therapy in late-life major depression in males. J Clin Psychiatry (United States), Dec 2002, 63(12) p1096-101
49) Anderson J.K., Faulkner S., Cranor C., et al. Andropause: knowledge and perceptions among the general public and health care professionals. J Gerontol A Biol Sci Med Sci (United States), Dec 2002, 57(12) pM793-6.
50) Okun M.S., Walter B.L., McDonald W.M., et al. Beneficial effects of testosterone replacement for the nonmotor symptoms of Parkinson disease. Arch Neurol (United States), Nov 2002, 59(11) p1750-3.
51) Kong .A, Edmonds P.. Testosterone therapy in HIV wasting syndrome: systematic review and meta-analysis. Lancet Infect Dis (United States), Nov 2002, 2(11) p692-9
52) Shors T.J., Miesegaes G.. Testosterone in utero and at birth dictates how stressful experience will affect learning in adulthood. Proc Natl Acad Sci U S A (United States), Oct 15 2002, 99(21) p13955-60.
53) Gapstur S.M., Gann P.H., Kopp P., et al. Serum androgen concentrations in young men: a longitudinal analysis associations with age, obesity, and race. The CARDIA male hormone study. Cancer Epidemiol Biomarkers Prev (United States), Oct 2002, 11(10 Pt 1) p1041-7.
54) Thum T., Borlak J.. Testosterone, cytochrome P450, and cardiac hypertrophy. FASEB J (United States), Oct 2002, 16(12) p1537-49.
55) Choi J., Silverman I.. The relationship between testosterone and route-learning strategies in humans. Brain Cogn (United States), Oct 2002, 50(1) p116-20.
56) Barud W., Palusinski R., Beltowski J ., et al. Inverse relationship between total testosterone and anti-oxidized low density lipoprotein antibody levels in ageing males. Atherosclerosis (Ireland), Oct 2002, 164(2) p283-8
57) von der P.B., Sarkola T., Seppa K., et al. Testosterone, 5 alpha-dihydrotestosterone and cortisol in men with and without alcohol-related aggression.J Stud Alcohol (United States), Sep 2002, 63(5) p518-26.
58) Roberts K.P. McLachlan et al (2002) ,point out the fact that mammalian spermatogenesis requires an intratesticular testosterone concentration many times higher than normal serum levels.J Androl (United States), Sep-Oct 2002, 23(5) p618.
59) Shirtcliff E.A., Granger D.A., Likos A.. Gender differences in the validity of testosterone measured in saliva by immunoassay. Horm Behav (United States), Aug 2002, 42(1) p62-9.
60) Martinez-Sanchis S., Aragon C.M., Salvador A.. Cocaine-induced locomotor activity is enhanced by exogenous testosterone. Physiol Behav (United States), Aug 2002, 76(4-5) p605-9.
61) Kerr C.: Depression eased for Parkinson males. Trends Endocrinol Metab (United States), Jul 2002, 13(5) p188.
62) Hewitt L.M., Smyth S.A., Dube M.G., et al. Isolation of compounds from bleached kraft mill recovery condensates associated with reduced levels of testosterone in mummichog (Fundulus heteroclitus). Environ Toxicol Chem (United States), Jul 2002, 21(7) p1359-67.
63) Sharpe R.M., Martin B., Morris K., et al. Infant feeding with soy formula milk: effects on the testis and on blood testosterone levels in marmoset monkeys during the period of neonatal testicular activity. Hum Reprod (England), Jul 2002, 17(7) p1692-703.
64) Fogari R., Preti P., Derosa G., et al. Effect of antihypertensive treatment with Valsartan or Atenolol on sexual activity and plasma testosterone in hypertensive men. Eur J Clin Pharmacol (Germany), Jun 2002, 58(3) p177-80
65) Ishizaka K., Suzuki M., Kageyama Y., et al. Bone mineral density in hypogonadal men remains low after long-term testosterone replacement. Asian J Androl (China), Jun 2002, 4(2) p117-21.
66) Guay A., Davis S.R.: Testosterone insufficiency in women: fact or fiction? World J Urol (Germany), Jun 2002, 20(2) p106-10.
67) Ballinger, A. B.. Savage, MARTIN. O. Sanderson, I. R.. Delayed Puberty Associated with Inflammatory Bowel Disease. Pediatric Research. 53(2):205-210, February 2003.
68) Papasozomenos S.Ch., Shanavas A.: Testosterone prevents the heat shock-induced over-activation of glycogen synthase kinase-3 beta but not of cyclin-dependent kinase 5 and c-Jun NH2-terminal kinase and concomitantly abolishes hyperphosphorylation of tau: implications for Alzheimer’s disease. Proc Natl Acad Sci U S A (United States), Feb 5 2002, 99(3) p1140-5
69) Wespes E., Schulman C.C.: Male andropause: myth, reality, and treatment. Int J Impot Res (England), Feb 2002, 14 Suppl 1 pS93-8.
70) Baker .L.A., Pearcey S.M., Dabbs J.M.: Testosterone, alcohol, and civil and rough conflict resolution strategies in lesbian couples. J Homosex (United States), 2002, 42(4) p77-88
71) Monga M., Kostelec M., Kamarei M.; Patient satisfaction with testosterone supplementation for the treatment of erectile dysfunction. Arch Androl (England), Nov-Dec 2002, 48(6) p433-42.
72) Hogervorst E, Lehmann DJ, Warden DR, et al. Apolipoprotein E epsilon4 and testosterone interact in the risk of Alzheimer’s disease in men. Int J Geriatr Psychiatry (England), Oct 2002, 17(10) p938-40
73) Aromaki A.S., Lindman R.E., Eriksson C.J. Testosterone, sexuality and antisocial personality in rapists and child molesters: a pilot study. Psychiatry Res (Ireland), Jul 31 2002, 110(3) p239-47.
74) Sinha-Hikim I., Artaza J., Woodhouse L., et al. Testosterone-induced increase in muscle size in healthy young men is associated with muscle fibre hypertrophy. Am J Physiol Endocrinol Metab (United States), Jul 2002, 283(1) pE154-64.
75) Zitzmann M., Junker R., Kamischke A., et al.: Contraceptive steroids influence the hemostatic activation state in healthy men. J Androl (United States), Jul-Aug 2002, 23(4) p503-11.
76) Jones R.D., English K.M., Pugh P.J., et al. Pulmonary vasodilatory action of testosterone: evidence of a calcium antagonistic action. J Cardiovasc Pharmacol (United States), Jun 2002, 39(6) p814-23.
77) Allen N.E., Appleby P.N., Davey G.K., et al. Lifestyle and nutritional determinants of bio-available androgens and related hormones in British men. Cancer Causes Control (Netherlands), May 2002, 13(4) p353-63.
78) Okun M.S., McDonald W.M., De Long M.R.: Refractory non-motor symptoms in male patients with Parkinson’s disease due to testosterone deficiency: a common unrecognized co-morbidity. Arch Neurol (United States), May 2002, 59(5) p807-11.
79) Rohr U.D.: The impact of testosterone imbalance on depression and women’s health. Maturitas (Ireland), Apr 15 2002, 41 Suppl 1 pS25-46.
80) O’Connor D.B., Archer J., Hair W.M., et al.: Exogenous Testosterone, aggression, and mood in eugonadal and hypogonadal men. Physiol Behav (United States), Apr 1 2002, 75(4) p557-66.
81) Kang SM., Jang Y., Kim J.Y., et al. ; Effect of oral administration of testosterone on brachial arterial vasoreactivity in men with coronary artery disease. Am J Cardiol (United States), Apr 1 2002, 89(7) p862-4.
82) Ortmann J., Prifti S., Bohlmann M.K., et al.: Testosterone and 5 alpha-dihydrotestosterone inhibit in vitro growth of human breast cancer cell lines. Gynecol Endocrinol (England), Apr 2002, 16(2) p113-20.
83) N. Meston, et al.: Endocrine effects of nasal continuous positive airway pressure in male patients with obstructive sleep apnoea. Journal of Internal Medicine 254: 447–454.
84 )Orengo C., Kunik M.E., Molinari V., et al.: Do testosterone levels relate to aggression in elderly men with dementia? J Neuropsychiatry Clin Neurosci (United States), Spring 2002, 14(2) p161-6.
85) Yaffe K., Lui L.Y., Zmuda J., et al. Sex hormones and cognitive function in older men. J Am Geriatr Soc (United States), Apr 2002, 50(4) p707-12.
86) Chatterjee R., Kottaridis P.D., McGarrigle H.H., et al. Management of erectile dysfunction by combination therapy with Testosterone and Sildenafil in recipients of high-dose therapy for haematological malignancies. Bone Marrow Transplant (England), Apr 2002, 29(7) p607-10.
87) Rolf C., von Eckardstein S., Koken U., et al.: Testosterone substitution of hypogonadal men prevents the age-dependent increases in body mass index, body fat and leptin seen in healthy ageing men: results of a cross-sectional study.Eur J Endocrinol (England), Apr 2002, 146(4) p505-11.
88) Nathan L., Shi W., Dinh H., et al.: Testosterone inhibits early atherogenesis by conversion to Estradiol: critical role of aromatase. Proc Natl Acad Sci U S A (United States), Mar 13 2001, 98(6) p3589-93.
89) Sowers M.F., Beebe J.L., McConnell D., et al.: Testosterone concentrations in women aged 25-50 years: associations with lifestyle, body composition, and ovarian status. Am J Epidemiol (United States), Feb 1 2001, 153(3) p256-64.
90) Peterson, Giwercman, Skakkebaek,and Rorth.: Gonadal Function in Men WithTesticular Cancer” from Seminars in Oncology, Vol 25(2), April 1998.
91) Maurer M., Trajanoski Z., Frey G., et al.: Differential gene expression profile of glucocorticoids, testosterone, and dehydroepiandrosterone in human cells. Horm Metab Res (Germany), Dec 2001, 33(12) p691-5.
92) Simon D., Charles M.A., Lahlou N., et al.: Androgen therapy improves insulin sensitivity and decreases leptin level in healthy adult men with low plasma total testosterone: a 3-month randomized placebo-controlled trial. Diabetes Care (United States), Dec 2001, 24(12) p2149-51.
93) Bhasin S., Woodhouse L., Casaburi R., et al.: Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab (United States), Dec 2001, 281(6) pE1172-81.
94) Pike C.J.: Testosterone attenuates beta-amyloid toxicity in cultured hippocampal neurons. Brain Res (Netherlands), Nov 16 2001, 919(1) p160-5.
95) Yu M.W., Yang Y.C., Yang S.Y., et al.: Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case-control study among men.J Natl Cancer Inst (United States), Nov 7 2001, 93(21) p1644-51.
96) Ishikawa A., Ishikawa S., Hirakawa M.: Osteoporosis, bone turnover and hypogonadism in elderly men with treated leprosy. Lepr Rev (England), Sep 2001, 72(3) p322-9.
97) Harris E., Mahendra P., McGarrigle H.H., et al.: Gynocomastia with hypergonadotrophic hypogonadism and Leydig cell insufficiency in recipients of high-dose chemotherapy or chemo-radiotherapy. Bone Marrow Transplant (England), Dec 2001, 28(12) p1141-4.
98) Celik S., Erdol C., Erem C., et al.: Echocardiographic evaluation in patients with hypogonadotropic hypogonadism. J Reprod Med (United States), Aug 2001, 46(8) p709-11.
99) Seminara S, Crowley W.F.: The genetics of IHH–a paradox.Clin Endocrinol (Oxf) (England), Aug 2001, 55(2) p159-60.
100) Singh A.B., Norris K., Modi N., et al.: Pharmakinetics of a transdermal testosterone system in men with end stage renal disease receiving maintenance haemodialysis and healthy hypogonadal men. J Clin Endocrinol Metab (United States), Jun 2001, 86(6) p2437-45.
101) Hayes V.Y., Urban R.J., Jiang J., Marcell T.J., Helgeson K., Mauras N.: Recombinant human growth hormone and recombinant human insulin-like growth factor I diminish the catabolic effects of hypogonadism in man: metabolic and molecular effects. J Clin Endocrinol Metab (United States), May 2001, 86(5) p2211-9.

102) Raman P.G., Shende A., Chakraborty D., et al.: 46 3q+ karyotype presenting as syndrome with obesity and hypogonadism. J Assoc Physicians India (India), Apr 2001, 49 p481-4.
103) De Rosa M., Paesano L., Nuzzo V., et al.: Bone mineral density and bone markers in hypogonadotropic and hypergonadotropic hypogonadal men after prolonged testosterone treatment. J Endocrinol Invest (Italy), Apr 2001, 24(4) p246-52.
104) Oktenli C., Koc B., Alis M, et al.: Unilateral renal agenesis and hypogonadotropic hypogonadism: an interesting coincidence. Clin Nephrol (Germany), Apr 2001, 55(4) p340-2
105) Macut D., Micic D., Zoric S., et al.: Decrease of serum leptin levels in adult male with idiopathic hypogonadotropic hypogonadism (IHH) treated with pulsatile gonadotropin-releasing hormone (GnRH). J Endocrinol Invest (Italy), Feb 2001, 24(2) p135-6.
106) Emanuele N..V, La Paglia N., Benefield J., et al.: Ethanol-induced hypogonadism is not dependent on activation of the hypothalamic-pituitary-adrenal axis. Endocr Res (United States), Nov 2001, 27(4) p465-72.
107) Baptista T., Lacruz A., Angeles F,. et al.: Endocrine and metabolic abnormalities involved in obesity associated with typical antipsychotic drug administration. Pharmacopsychiatry (Germany), Nov 2001, 34(6) p223-31.
108) Komesaroff P.A., Fullerton M., Esler M.D., et al.: Low-dose Estrogen supplementation improves vascular function in hypogonadal men. Hypertension (United States), Nov 2001, 38(5) p1011-6.
109) Whitsel E.A., Boyko E.J., Matsumoto A.M., et al.: Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis.Am J Med (United States), Sep 2001, 111(4) p261-9.
110) Bouloux P.M., Handelsman D.J., Jockenhovel F., et al.: First human exposure to FSH-CTP in hypogonadotrophic hypogonadal males. Hum Reprod (England), Aug 2001, 16(8) p1592-7.
111) Wang C., Swerdloff R.S., Iranmanesh A., et al.: Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clin Endocrinol (Oxf) (England), Jun 2001, 54(6) p739-50.
112) Katznelson L., Kleinberg D., Vance M.L., et al.: Hypogonadism in patients with Acromegaly: data from the multi-centre acromegaly registry pilot study. Clin Endocrinol (Oxf) (England), Feb 2001, 54(2) p183-8.
113) O’Connor D.B., Archer J., Hair W.M., et al.: Activational effects of testosterone on cognitive function in men. Neuropsychologia (England), 2001, 39(13) p1385-94.
114) Cutter C.B. Compounded percutaneous testosterone gel: use and effects in hypogonadal men. J Am Board Fam Pract (United States), Jan-Feb 2001, 14(1) p22-32.
115) Fairfield W.P., Finkelstein J.S., Klibanski A., et al.: Osteopenia in eugonadal men with acquired immune deficiency syndrome wasting syndrome. J Clin Endocrinol Metab (United States), May 2001, 86(5) p2020-6.
116) Lindqvist A., Hughes I.A., Andersson S.: Substitution mutation C268Y causes 17 beta-hydroxysteroid dehydrogenase 3 deficiency. J Clin Endocrinol Metab (United States), Feb 2001, 86(2) p921-3.
117) Voskaridou E., Kyrtsonis M.C., Terpos E., et al.: Bone resorption is increased in young adults with thalassaemia major. Br J Haematol (England), Jan 2001, 112(1) p36-41.
118) Howell S., Shalet S.: Testosterone deficiency and replacement. Horm Res (Switzerland), 2001, 56 Suppl 1 p86-92.
119) Zitzmann M., Weckesser M., Schober O., et al.: Changes in cerebral glucose metabolism and visuospatial capability in hypogonadal males under testosterone substitution therapy. Exp Clin Endocrinol Diabetes (Germany), 2001, 109(5) p302-4.
120) Prasad A.S.: Discovery of human zinc deficiency: impact on human health. Nutrition (United States), Jul-Aug 2001, 17(7-8) p685-7.
121) Martin J.A., Hamilton B.E., Ventura S.J., Menacker F., Park M.M.. : NVSS Births: Final Data for 2000 Volume 50, Number 5 February 12, 2002 PDF
122) Cushman L.J., Watkins-Chow D.E., Brinkmeier M.L., et al: Persistent Prop1 expression delays gonadotrope differentiation and enhances pituitary tumor susceptibility. Hum Mol Genet (England), May 15 2001, 10(11) p1141-53.
123) Tenover JS.Prevalence and management of mild hypogonadism: introduction.Int J Impot Res. 2003 Aug;15 Suppl 4:S1-2.
124) Buchacz, K., Rogol, A.D,. Lindsey, J.C. et al.
Pediatric AIDS Clinical Trials Group 219 Study Team.: Delayed Onset of Pubertal Development in Children and Adolescents With Perinatally Acquired HIV Infection. JAIDS Journal of Acquired Immune Deficiency Syndromes. 33(1):56-65, May 1, 2003.
125) Prasad A.S.: Recognition of zinc-deficiency syndrome.Nutrition (United States), Jan 2001, 17(1) p67-9126) Zhao L., Bakke M., Krimkevich Y., et al.: Steroidogenic factor 1 (SF1) is essential for pituitary gonadotrope function. Development (England), Jan 2001, 128(2) p147-54
127) Gasser R.W.: Androgen therapy from the viewpoint of the internal medicine physician. Wien Med Wochenschr (Austria), 2001, 151(18-20) p444-7.
128) Gunay-Aygun M.: The changing purpose of Prader-Willi syndrome clinical diagnostic criteria and proposed revised criteria. Pediatrics (United States), Nov 2001, 108(5) pE92.
129) Nindl B.C., Kraemer W.J., Deaver D.R., et al.: LH secretion and testosterone concentrations are blunted after resistance exercise in men. J Appl Physiol (United States), Sep 2001, 91(3) p1251-8.
130) Bhasin S, Woodhouse L., Storer T.W.: Proof of the effect of testosterone on skeletal muscle. J Endocrinol (England), Jul 2001, 170(1) p27-38.
130) Kao J.S., Garg A., Mao-Qiang M., et al.: Testosterone perturbs epidermal permeability barrier homeostasis. J Invest Dermatol (United States), Mar 2001, 116(3) p443-51.
131) Otonicar B., Velikonja V. Zorn B.: Personality traits of men with Klinefelter syndrome and their partners. Gynecol Obstet Fertil (France), Feb 2001, 29(2) p123-8.
132) La Montagna G., Baruffo A., Pasquali D., et al.: Assessment of pituitary gonadotropin release to gonadotropin releasing hormone/thyroid-stimulating hormone stimulation in women with systemic sclerosis. Rheumatology (Oxford) (England), Mar 2001, 40(3) p310-4.
133) Bodie, J., Lewis, J., Schow, D. et al.:
Laboratory Evaluations of Erectile Dysfunction: An Evidence Based Approach. Journal of Urology. 169(6):2262-2264, June 2003.
134) Tan R.S., Pu S.J.: The Andropause and memory loss: is there a link between androgen decline and dementia in the aging male? Asian J Androl (China), Sep 2001, 3(3) p169-74.
135) Rajagopalan B.: The ‘hook effect’ on serum Prolactin estimation in a patient with macroprolactinoma. Neurol India (India), Mar 2001, 49(1) p78-80.
136) Meyenburg B., Sigusch V.: Kallmann’s syndrome and transsexualism. Arch Sex Behav (United States), Feb 2001, 30(1) p75-81.
137) Zietz, B., Lock, G., Plach, B., et al. Dysfunction of the hypothalamic-pituitary-glandular axes and relation to Child-Pugh classification in male patients with alcoholic and virus-related cirrhosis. European Journal of Gastroenterology & Hepatology. 15(5):495-501, May 2003.
138) Nathan L., Shi W., Dinh H., et al.: Testosterone inhibits early atherogenesis by conversion to estradiol: critical role of aromatase. Proc Natl Acad Sci U S A (United States), Mar 13 2001, 98(6) p3589-93.
139) Hohlagschwandtner M., Husslein P., Klier C., et al.L: Correlation between serum testosterone levels and peripartal mood states. Acta Obstet Gynecol Scand (Denmark), Apr 2001, 80(4) p326-30.
140) Davis S.R., Tran J Testosterone influences libido and well being in women. Trends Endocrinol Metab (United States), Jan-Feb 2001, 12(1) p33-7.
141) Brill K.T., Weltman A.L., Gentili A., et al.: Single and combined effects of growth hormone and testosterone administration on measures of body composition, physical performance, mood, sexual function, bone turnover, and muscle gene expression in healthy older men. J Clin Endocrinol Metab (United States), Dec 2002, 87(12) p5649-57.
142) O’Connor D.B., Archer J., Hair W.M., et al.: Exogenous testosterone, aggression, and mood in eugonadal and hypogonadal men. Physiol Behav (United States), Apr 1 2002, 75(4) p557-66.
143) Filaire E., Bernain X., Sagnol M., et al.: Preliminary results on mood state, salivary testosterone:cortisol ratio and team performance in a professional soccer team. Eur J Appl Physiol (Germany), Dec 2001, 86(2) p179-84.
144) Young E.A., Korszun A.: The hypothalamic-pituitary-gonadal axis in mood disorders. Endocrinol Metab Clin North Am (United States), Mar 2002, 31(1) p63-78.
145) Tan R.S. Andropause and testosterone supplementation for cognitive loss. J Androl (United States), Jan-Feb 2002, 23(1) p45-6
146) Margolese H.C.: The male menopause and mood: testosterone decline and depression in the aging male–is there a link? J Geriatr Psychiatry Neurol (Canada), Summer 2000, 13(2) p93-101.
147) Rashid W.: Testosterone abuse and affective disorders. J Subst Abuse Treat (United States), Mar 2000, 18(2) p179-84.
148) Testosterone and depression in men.Treatment update (Canada), May 2000, 12(3) p7-8
149) Street M.E., Bandello M.A., Terzi C., et al.:  Leuteinizing hormone responses to leuprolide acetate discriminate between hypogonadotropic hypogonadism and constitutional delay of puberty. Fertil Steril (United States), Mar 2002, 77(3) p555-60.
150) Vierhapper H.; Nowotny P.; Waldhaus l. W.: Reduced production rates of testosterone and Dihydrotestosterone in healthy men treated with Rosiglitazone. [In Process Citation] Metabolism 2003 Feb;52(2):230-2 (ISSN: 0026-0495).
151) Kumanov P., Tomova A., Kirilov G., et al.: Increased plasma endothelin levels in patients with male hypogonadism. Andrologia (Germany), Feb 2002, 34(1) p29-33.
152) Kebers F., Janvier S., Colin A., Legros J.J., Ansseau M.: What is the interest of Klinefelter’s syndrome for (child) psychiatrists? Encephale 2002 May-Jun;28(3 Pt 1):260-5.
153) Hanaoka T., Kawamura N., Hara K., et al.: Urinary Bisphenol A and plasma hormone concentrations in male workers exposed to Bisphenol A Diglycidyl Ether and mixed organic solvents. Occup Environ Med (England), Sep 2002, 59(9) p625-8.
154) Tan R.S., Pu S.J.: Impact of obesity on hypogonadism in the Andropause. Int J Androl (England), Aug 2002, 25(4) p195-201.

155) Abate N., Haffner S.M., Garg A., et al.: Sex steroid hormones, upper body obesity, and insulin resistance.: J Clin Endocrinol Metab (United States), Oct 2002, 87(10) p4522-7.
156) Burger H.G., Davis S.R.: The role of androgen therapy. Best Pract Res Clin Obstet Gynaecol (England), Jun 2002, 16(3) p383-93.
157) MacColl G., Quinton R., Bouloux P.M.: GnRH neuronal development: insights into hypogonadotrophic hypogonadism. Trends Endocrinol Metab (United States), Apr 2002, 13(3) p112-8.
158)  Creutzberg,E.C.  Casaburi R.: Endocrinological disturbances in chronic obstructive pulmonary disease.
Eur Respir J 2003; 22: Suppl. 46, 76s–80s.
159) Baumbach J.: Some implications of prenatal alcohol exposure for the treatment of adolescents with sexual offending behaviours. Sex Abuse (United States), Oct 2002, 14(4) p313-27.
160) Trummer H., Habermann H., Haas J., et al.: The impact of cigarette smoking on human semen parameters and hormones. Hum Reprod (England), Jun 2002, 17(6) p1554-9.
161) Frias J., Rodriguez R., Torres J.M., et al.: Effects of acute alcohol intoxication on pituitary-gonadal axis hormones, pituitary-adrenal axis hormones, beta-endorphin and prolactin in human adolescents of both sexes. Life Sci (England), 2000, 67(9) p1081-6.
162) Bedecarrats G.Y. et al.: Four naturally occurring mutations in the human GnRH receptor affect ligand binding and receptor function. Molecular and Cellular Endocrinology 205 (2003) 51/64.
163) Rolf C., Knie U., Lemmnitz G., Nieschlag E.: Interpersonal Testosterone transfer after topical application of a newly developed testosterone gel preparation. Institute of Reproductive Medicine of the University, Domagkstrasse 11, D-48129 Munster, Germany.
164) McGriff-Lee N.J.: Transdermal testosterone gel (Cellegy). [In Process Citation] Curr Opin Investig Drugs (England), Nov 2002, 3(11) p1629-32.
165) McNicholas T.A., Dean J.D., Mulder H., et al.: A novel Testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. [In Process Citation] BJU Int (England), Jan 2003, 91(1) p69-74.
166) Mockel J., Schulman C., Sternon J.: [Partial androgenic deficit in the aging male]. Rev Med Brux (Belgium), Oct 2002, 23(5) p451-5.
167) Ling S., Dai A, Williams M.R., et al.:Testosterone (T) enhances apoptosis-related damage in human vascular endothelial cells. Endocrinology (United States), Mar 2002, 143(3) p1119-25.
168) Rolf C., Kemper S., Lemmnitz G., et al.: Pharmacokinetics of a new transdermal testosterone gel in gonadotrophin-suppressed normal men. Eur J Endocrinol (England), May 2002, 146(5) p673-9.
169) Bojesen A., Juul S. and Højbjerg Gravholt C.:
Prenatal and Postnatal Prevalence of Klinefelter Syndrome: A National Registry Study. JCEM Vol. 88, No. 2 622-626
170) Vastag B.: Many Questions Few Answers For Testosterone Replacement Therapy. JAMA February 26 2003 971 – 974.
171) Sas, T. C. et al.: Bone Mineral Density Assessed by Phalangeal Radiographic Absorptiometry Before and During Long-Term Growth Hormone Treatment in Girls with Turner’s Syndrome Participating in a Randomized Dose-Response Study. Pediatric Research 50 (2001): 417-422. September 2001.
172) Silveira, L. F.G.,  MacColl, G. S., Bouloux, P.M.G. : Hypogonadotropic Hypogonadism. Seminars in Reproductive Medicine. Neuroendocrine Disorders and Reproduction. 20(4):327-338, 2002.
173) Mazer, N.A., Shifren, J. L. : Transdermal Testosterone for Women:: A New Physiological Approach for Androgen Therapy. Obstetrical & Gynecological Survey. 58(7):489-500, July 2003.
174) Zitzmann M., Depenbusch M,, Gromoll J,, et al.:
Prostate volume and growth in testosterone-substituted hypogonadal men are dependent on the CAG repeat polymorphism of the androgen receptor gene: a longitudinal pharmacogenetic study. J Clin Endocrinol Metab (United States), May 2003, 88(5) p2049-54.
175) Tan R.S., Pu S.J.: A pilot study on the effects of testosterone in hypogonadal aging male patients with Alzheimer’s disease. Aging Male (United States), Mar 2003, 6(1) p13-7.
176) Mainieri A.S., Elnecave R.H.: Usefulness of the free -subunit to diagnose hypogonadotropic hypogonadism.
Clinical Endocrinology, September 2003, vol. 59, no. 3, pp. 307-313(7).
177)  Tibblin G., Adlerberth, A.,  Lindstedt, G., Bjorntorp P,.: .
The pituitary-gonadal axis and health in elderly men: a study of men born in 1913. Diabetes, Vol 45, Issue 11 1605-1609,
178) Jimenez-Balderas, Tapia-Serrano, Fonseca, et al: High frequency of association of rheumatic/autoimmune diseases and untreated male Hypogonadism with severe testicular dysfunction. Arthritis Res. 2001; 3 (6): 362–367.
179) Semple C., Robertson W., Mitchell R., Gordon D., et al:
Mechanisms leading to hypogonadism in men with burns injuries. Br Med J (Clin Res Ed) 1987 Aug 15;295(6595):403-7
180)  Safarinjad M. R., Level of injury and hormone profiles in Spinal Cord-injured men. UROLOGY 58: 671–676, 2001.
181) Burman P., Ritze E.M., Lindgren A.C.: Endocrine Dysfunction in Prader-Willi Syndrome:A Review with Special Reference to GH. Endocrine Reviews 22(6):787–799.
182) Paris I., Hermans M., Buysschaert M.: Endocrine complications of genetic Hemochromatosis. Acta Clin Belg 1999 Dec;54(6):334-45.
183) Schmidt A., Luger A., Horl W.H.: Sexual hormone abnormalities in male patients with renal failure. Nephrol Dial Transplant (2002) 17: 368–371.
184) Okun M.S., Walter B.L., McDonald W.M., Tenover J.L., Green J., Juncos J.L., DeLong M.R.: Beneficial effects of testosterone replacement for the non-motor symptoms of Parkinson disease. Arch Neurol. 2002 Nov;59(11):1750-3.
185)  Stempfle H.U., Stief J.P., Überfuhr P.,  Theisen K., and  Sohn H.Y.: The role of hypogonadism on bone loss after cardiac transplantation: is a testosterone replacement therapy necessary?. The Journal of Heart and Lung Transplantation, Volume 23, Issue 2, Supplement 1, February 2004, Page S111.
186) Laaksonen D. E.. Niskanen, Punnonen K., Nyyssonen K., Tuomainen T., Valkonen V., Salonen R., Salonen J.T.:
Testosterone and Sex Hormone-Binding Globulin Predict the Metabolic Syndrome and Diabetes in Middle-Aged Men. Diabetes Care. 27(5):1036-1041, May 2004.

187) Norda C., Bjørob T., Ellingsenc D., Mykletund A., Dahle O., Kleppf O., Bremnesg R.M., Wisth E., Fossa° S.
Gonadal Hormones in Long-Term Survivors 10 Years after Treatment for Unilateral Testicular Cancer. European Urology 44 (2003) 322–328
188) Maffei L,. Murata Y,. Rochira V,. Tubert G,. Aranda C,. Vazquez M,. Clyne C.D., Davis S., Simpson E.R., Carani C.:
Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment. J Clin Endocrinol Metab 2004 Jan;89(1):61-70 (ISSN: 0021-972X).
189) Miller K.K., Rosner W., Lee H., et al.: Measurement of free testosterone in normal women and women with androgen deficiency: comparison of methods. J Clin Endocrinol Metab (United States), Feb 2004, 89(2) p525-33.
190) Morris P.D.. Malkin C.J.. Channer K.S.. Jones T.H.:
A mathematical comparison of techniques to predict biologically available testosterone in a cohort of 1072 men.
European Journal of Endocrinology. 151(2):241-9, 2004 Aug.
191) Malkin, C.J.,  Pugh, P.J.,  Morris, P.D.,  Kerry, K.E., Jones, R.D., Jones, T.H., Channer , K.S.: Testosterone replacement in Hypogonadal men with Angina improves Ischaemic threshold and quality of life. Heart 2004;90:871–876.
192) Dhindsa S., Prabhakar S., Sethi M., Bandyopadhyay A., Chaudhuri A., and Dandona P.: Frequent Occurrence of Hypogonadotropic Hypogonadism in Type 2 Diabetes.
The Journal of Clinical Endocrinology & Metabolism Vol. 89, No. 11 5462-5468

193)
Araujo AB, O’Donnell AB, Brambilla DJ, et al.: Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study.
J Clin Endocrinol Metab (United States), Dec 2004, 89(12) p5920-6
194) Grumbach M.M.: A Window of Opportunity: The Diagnosis of Gonadotropin Deficiency in the Male Infant.
J Clin Endocrinol Metab (United States), Feb 22 2005
195) Agarwal P.K.; Oefelein M.G.: Testosterone replacement therapy after primary treatment for prostate cancer. J Urol 2005 Feb;173(2):533-6 (ISSN: 0022-5347).
196) O’Keane V., Meaney A.M.: Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia? [In Process Citation]. J Clin Psychopharmacol (United States), Feb 2005, 25(1) p26-31.
197) Searle L.C., Graham J.M., Prasad C., et al.: CHARGE syndrome from birth to adulthood: An individual reported on from 0 to 33 years. Am J Med Genet A (United States), Mar 15 2005, 133(3) p344-9.
198) Roste L.S., Tauboll E., Morkrid L., et al.: Antiepileptic drugs alter reproductive endocrine hormones in men with epilepsy.  Eur J Neurol (England), Feb 2005, 12(2) p118-24
198) Huber T.J., Tettenborn C., Leifke E., et al.: Sex hormones in psychotic men. Psychoneuroendocrinology (England), Jan 2005, 30(1) p111-4.
199) Hayes F.J.; Seminara S.B.; Decruz S.; Boepple P.A.; Crowley W.F.: Aromatase inhibition in the human male reveals a hypothalamic site of estrogen feedback. J Clin Endocrinol Metab 2000 Sep;85(9):3027-35 (ISSN: 0021-972X).
200) Hashemi S.J., Sarasgani M.R., Zomorodian K.: A comparative survey of serum androgenic hormones levels between male patients with Dermatophytosis and normal subjects. Jpn J Infect Dis 2004 Apr;57(2):60-2 (ISSN: 1344-6304).

201) Ulug U.; Ben-Shlomo I.; Tosun S.; Erden H.F.; Akman M.A.; Bahceci M.: The reproductive performance of women with hypogonadotropic hypogonadism in an in vitro fertilization and embryo transfer program. J Assist Reprod Genet 2005 Apr;22(4):167-71 (ISSN: 1058-0468).
202) Kuhnert B.; Byrne M.; Simoni M.; Kopcke W.; Gerss J.; Lemmnitz G.; Nieschlag E.: Testosterone substitution with a new transdermal, hydroalcoholic gel applied to scrotal or non-scrotal skin: a multicentre trial. Eur J Endocrinol 2005 Aug;153(2):317-26 (ISSN: 0804-4643).
203) Benito M.; Vasilic B.; Wehrli F.W.; Bunker B.; Wald M.; Gomberg B.; Wright A.C.; Zemel B.; Cucchiara A.; Snyder P.J.: Effect of testosterone replacement on trabecular architecture in hypogonadal men [In Process Citation].
J Bone Miner Res 2005 Oct;20(10):1785-91 (ISSN: 0884-0431).
204) Makhsida N.; Shah J.; Yan G.; Fisch H.; Shabsigh R.\;
Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol 2005 Sep;174(3):827-34 (ISSN: 0022-5347)
205) Miller, Biller, Beauregard, Lipman, Jones, Schoenfeld, Sherman, Swearingen, Loeffler and Klibanski: Effects of Testosterone Replacement in Androgen-Deficient Women with Hypopituitarism: A Randomized, Double-Blind, Placebo-Controlled Study. J Clin Endocrin Metab. First published February 14, 2006 as doi:10.1210/jc.2005-2596
206) Chik Z., Johnston A., Tucker A.T., Chew S.L., Michaels L., Alam C.\: Pharmacokinetics of a new testosterone transdermal delivery system, TDS-testosterone in healthy males. Br J Clin Pharmacol. 2006 Mar;61(3):275-9.
207) Akhondzadeh S., Rezaei F., Larijani B., Nejatisafa A.A., Kashani L., Abbasi S.H.: Correlation between testosterone, gonadotropins and prolactin and severity of negative symptoms in male patients with chronic schizophrenia.
Schizophr Res. 2006 Mar 15 [Epub ahead of print].
208) Hamed S., Mohamed K., El-Taher A., Hamed E., Omar H.: The sexual and reproductive health in men with generalized epilepsy: a multidisciplinary evaluation. Int J Impot Res. 2006 May-Jun;18(3):287-95.
209) Malkin C.J., Jones T.H., Channer K.S.: The effect of testosterone on insulin sensitivity in men with heart failure.
Eur J Heart Fail. 2006 Jul 5; [Epub ahead of print]
210) Ferrucci L., Maggio M., Bandinelli S., Basaria S., Lauretani F., Ble A., Valenti G., Ershler W.B., Guralnik J.M., Longo D.L.: Low testosterone levels and the risk of anemia in older men and women. Arch Intern Med. 2006 Jul 10;166(13):1380-8.
211) Kumanov P., Tomova A., Kirilov G.: Testosterone replacement therapy in male hypogonadism is not associated with increase of endothelin-1 levels. Int J Androl. 2006 Jul 24; [Epub ahead of print]
212) Bojesen A., Kristensen K., Birkebaek N.H., Fedder J., Mosekilde L., Bennett P., Laurberg P., Frystyk J., Flyvbjerg A., Christiansen J.S., Gravholt C.H.. The metabolic syndrome is frequent in Klinefelter’s syndrome and is associated with abdominal obesity and hypogonadism. Diabetes Care. 2006 Jul;29(7):1591-8.
213) Rosario P.W., Barroso A.L., Rezende L.L., Padrao E.L., Borges M.A., Guimaraes V.C., Purisch S.: Testicular function after Radioiodine therapy in patients with thyroid cancer.
Thyroid. 2006 Jul;16(7):667-70.
214) Foresta C, Caretta N., Lana A., De Toni L., Biagioli A., Ferlin A., Garolla A.: Reduced number of circulating endothelial progenitor cells in hypogonadal men. J Clin Endocrinol Metab. 2006 Aug 22; [Epub ahead of print]
215) Morgentaler A.: Testosterone Therapy for Men at Risk for or with History of Prostate Cancer. Curr Treat Options Oncol. 2006 Sep;7(5):363-369.
216)  Shores,M.M.,  Matsumoto, A.M.; Sloan, K. L.; Kivlahan, D.R.: Low Serum Testosterone and Mortality in Male Veterans. Arch Intern Med. 2006;166:1660-1665.
217) Turhan S., Tulunay C., Gulec S., Ozdol C., Kilickap M., Altn T., Gerede M., Erol C.: The association between androgen levels and premature coronary artery disease in men. Coron Artery Dis. 2007 May;18(3):159-62.
218) Wunder D.M., Bersinger N.A., Fux C.A., Mueller N.J., Hirschel B., Cavassini M., Elzi L., Schmid P., Bernasconi E., Mueller B., Furrer H.: Swiss HIV Cohort Study.
Short communication hypogonadism in HIV-1-infected men is common and does not resolve during antiretroviral therapy.
Antivir Ther. 2007;12(2):261-5.
219) Yeap B.B., Almeida O.P., Hyde Z., Norman P.E., Chubb S.A., Jamrozik K., Flicker L.: In men older than 70 years, total testosterone remains stable while free testosterone declines with age. The Health in Men Study. Eur J Endocrinol. 2007 May;156(5):585-94.
220) Kapoor D., Clarke S., Stanworth R., Channer K.S., Jones T.H. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 Diabetes. Eur J Endocrinol. 2007 May;156(5):595-602.
221) Martin D.M., Wittert G., Burns N.R.: Gonadal steroids and visuo-spatial abilities in adult males: implications for generalized age-related cognitive decline. Aging Male. 2007 Mar;10(1):17-29.
222) Kalyani, R.R.; Dobs, A.S.  ndrogen deficiency, diabetes, and the metabolic syndrome in men.
Current Opinion in Endocrinology, Diabetes & Obesity. 14(3):226-234, June 2007.
223) de Ronde, W.: Therapeutic uses of aromatase inhibitors in men. Current Opinion in Endocrinology, Diabetes & Obesity. 14(3):235-240, June 2007.
224) Lackner J.E., Mark I., Schatzl G., Marberger M., Kratzik C.: Hypogonadism and androgen deficiency symptoms in testicular cancer survivors. Urology. 2007 Apr;69(4):754-8.